KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Assets (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Assets readings, the most recent being $465.9 million for Q4 2025.

  • On a quarterly basis, Assets rose 35.5% to $465.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $465.9 million, a 35.5% increase, with the full-year FY2025 number at $465.9 million, up 35.5% from a year prior.
  • Assets hit $465.9 million in Q4 2025 for Esperion Therapeutics, up from $364.0 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $465.9 million in Q4 2025 to a low of $205.8 million in Q4 2023.
  • Median Assets over the past 5 years was $313.5 million (2022), compared with a mean of $308.6 million.
  • Biggest five-year swings in Assets: tumbled 35.02% in 2022 and later surged 67.07% in 2024.
  • Esperion Therapeutics' Assets stood at $381.6 million in 2021, then tumbled by 35.02% to $247.9 million in 2022, then fell by 17.0% to $205.8 million in 2023, then soared by 67.07% to $343.8 million in 2024, then skyrocketed by 35.5% to $465.9 million in 2025.
  • The last three reported values for Assets were $465.9 million (Q4 2025), $364.0 million (Q3 2025), and $347.1 million (Q2 2025) per Business Quant data.